mitapivat: Clinical Trials

11 trials of mitapivat, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

10 completed, 1 active not recruiting. 11 Phase 1, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 111Completed 10, Active not recruiting 1
Phase 21Active not recruiting 1

Follow mitapivat: new trials by email Literature Review of mitapivat trials Research Report on mitapivat

Trials (filtered) newest first · largest first

All 11 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study of How Mitapivat Affects Midazolam Blood Levels in Healthy Participants
Mitapivat, Midazolam - Healthy Participants
Phase 1CompletedAgios Pharmaceuticals, Inc.202024-10-172025-01-28
A Pharmacokinetic Study of Mitapivat in Participants With Moderate Hepatic Impairment Compared to Matched Healthy Control Participants With Normal Hepatic Function
Mitapivat - Moderate Hepatic Impairment
Phase 1CompletedAgios Pharmaceuticals, Inc.202023-01-102023-09-21
A Study to Compare the Pharmacokinetics and Safety of Mitapivat 100 mg Tablet Formulation With Mitapivat 2 × 50 mg Tablet Formulation in Healthy Adult Participants
Mitapivat tablet - Healthy Volunteers
Phase 1CompletedAgios Pharmaceuticals, Inc.262021-01-062021-04-13
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Long-term Mitapivat Dosing in Subjects With Stable Sickle Cell Disease: An Extension of a Phase I Pilot Study of Mitapivat
Mitapivat - Sickle Cell Disease, Hemolytic Anemia
Phase 1 / Phase 2Active not recruitingNational Heart, Lung, and Blood Institute (NHLBI)152020-12-092026-11-17
A Study to Assess the Relative Bioavailability and Effect of Food on the Coated Granule Formulation of Mitapivat in Healthy Participants
Mitapivat tablets, Mitapivat coated granules - Healthy Volunteers
Phase 1CompletedAgios Pharmaceuticals, Inc.322020-09-212020-12-10
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Mitapivat (AG-348) in Healthy Adult Participants
Placebo for Treatment A, Mitapivat 100 mg, Placebo for Treatment B - Healthy Volunteers
Phase 1CompletedAgios Pharmaceuticals, Inc.322020-06-172021-02-18
Study to Evaluate the Effect of Multiple Doses of Itraconazole and Rifampin on the Single-Dose Pharmacokinetics of Mitapivat Sulfate (AG-348) in Healthy Adult Participants
itraconazole, rifampin, mitapivat sulfate - Healthy Volunteers
Phase 1CompletedAgios Pharmaceuticals, Inc.282019-06-202019-10-23
A Study to Evaluate the Absorption, Distribution, Metabolism, Excretion and Absolute Bioavailability of AG-348 in Healthy Male Participants Following Administration of a Single Oral Dose of [14C]AG-348 and Concomitant Single Intravenous Microdose of [13C6]AG-348
AG-348, [13C6]AG-348 - Healthy Volunteers
Phase 1CompletedAgios Pharmaceuticals, Inc.82018-05-242018-10-12
Study to Evaluate the Pharmacokinetics, Safety, and QTc Effect of AG-348 in Healthy Subjects of Japanese Origin and Non-Asian Origin
AG-348 - Healthy, Japanese
Phase 1CompletedAgios Pharmaceuticals, Inc.602017-08-092017-10-19
A Phase I Study of AG-348 in Healthy Volunteers
AG-348, Placebo - Healthy Volunteer
Phase 1CompletedAgios Pharmaceuticals, Inc.482014-05-012014-11-10
A Phase I Study of AG-348 in Healthy Volunteers
AG-348, Placebo - Healthy Volunteer
Phase 1CompletedAgios Pharmaceuticals, Inc.482014-03-012014-10-22

Conditions studied

Anemia, Hemolytic (1)  ·  Anemia, Sickle Cell (1)

Sponsors

Agios Pharmaceuticals, Inc. (10)  ·  National Heart, Lung, and Blood Institute (NHLBI) (1)

Countries

United States (11)

Top investigators

Samuel Agresta, MD, MPH & TM (2)  ·  Swee Lay Thein, M.D. (1)

Results publications

PMID 30091852, PMID 38450513, PMID 41809202